Immunoglobulin G4 Related Disease clinical trials

Explore recruiting immunoglobulin g4 related disease clinical trials.

Recruiting immunoglobulin g4 related disease studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunoglobulin G4 Related Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease.

Netherlands, Italy, Germany, Poland, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

Netherlands, Spain, France, Belgium, Sweden, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)

Greece, Poland, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Immunoglobulin G4 Related Disease trials by city

Immunoglobulin G4 Related Disease clinical trials

Recruiting immunoglobulin g4 related disease studies right now

A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Short-term Glucocorticoid Combined with MMF for IgG4-RD

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

Also recruiting in Europe

A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease.

A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)

Immunoglobulin G4 Related Disease trials by city

Other conditions